Ensuring that clinical trials, once launched, successfully complete and generate useful knowledge is an important and indeed ethically imperative goal, given the risks and burdens borne by research participants. Since there are insufficient willing research participants to power all the trials that are currently undertaken,1 addressing underenrolment will require prioritisation decisions that reduce the number of trials competing for participants. While there are multiple levels at which research priority-setting can and does take place, competition between trials often plays out in real time at the institutional or site level, where complex decisions must be made about how to manage overlapping trials in ways that balance different considerations, including the risk of non-completion. We sought to explore what research institutions in particular might ethically do to mitigate the risk that competition between trials will contribute to recruitment shortfalls.
Published in:BIO International Convention, San Diego CA
Dr. Willyanne DeCormier Plosky, Program Manager at the MRCT Center, presented on this panel, which explored emerging principles and concrete strategies for addressing demographic disparities and achieving representativeness in clinical trials. The panel was organized and moderated by Lindsay Cobbs (BeiGene USA Inc.), and also included Melika Davis (BeiGene USA Inc.), Jacqueline Corrigan-Curay (FDA); Meg Alexander (Ovid Therapeutics Inc.), and Tesheia Johnson (Yale University) as speakers. See the recording here.
Published in:BIO International Convention, San Diego CA
Dr. Willyanne DeCormier Plosky, Program Manager at the MRCT Center, presented on this panel, which was organized by the MRCT Center to discuss the origins, development, structure, and lessons learned from pilot testing of the Equity by Design (EbD) in Clinical Research Metrics Framework. The panel was moderated by Camelia Thompson (BIO), and also included Neha Londono (Seagen Inc.); and Inez Ruiz-White (Otsuka Pharmaceuticals) as speakers. See the recording here.
